Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) announced that its self-developed innovative biologic drug T-Bren (HER2 ADC), a HER2-targeting novel ADC with Best-in-Class potential, has demonstrated significant antitumor efficacy in clinical trials. The drug, intended for HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma patients who have failed first-line anti-HER2 therapy and first-line standard chemotherapy, has been included in the Breakthrough Therapy List by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The public notice process has recently been completed.